Since its inception, OSE Immunotherapeutics has collaborated with leading academic teams in the fields of immunology and oncology.
In France
With the INSERM (French National Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), Nantes University, the Centre Léon Bérard of Lyon (affiliated to the National Federation of Centers for the Fight Against Cancer – Unicancer).
In Europe
With the Children’s Cancer Research Institute of Vienna-Austria, the Biomedical Primate Research Center in the Netherlands or Oxford University in the UK, the Kiel University (Germany).
In the United States
With the University of Maryland in Baltimore, the Ben Towne Center for Childhood Cancer Research in Seattle.
R&D Programs
In addition to its wide network of collaborations with top academic centers around the world, OSE Immunotherapeutics is involved in various research and development programs conducted within collaborative consortiums, both funded by partner Bpifrance, a French public investment bank, including:
- EFFIMab, to support OSE-127 development until Phase 2 in collaboration with the INSERM and the Nantes University Hospital;
- EFFI-CLIN, to support BI 765063 development up to the end of Phase 2 in collaboration with the European Center for Transplant and Immunotherapy Sciences (CESTI) and Histalim, a company specialized in immunohistochemistry.